Brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to post earnings per share of $0.02 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Acorda Therapeutics’ earnings, with the highest EPS estimate coming in at $0.32 and the lowest estimate coming in at ($0.34). Acorda Therapeutics posted earnings per share of $0.43 during the same quarter last year, which would suggest a negative year-over-year growth rate of 95.3%. The business is scheduled to report its next earnings results on Tuesday, October 30th.

According to Zacks, analysts expect that Acorda Therapeutics will report full-year earnings of $0.59 per share for the current financial year, with EPS estimates ranging from ($0.05) to $1.61. For the next year, analysts anticipate that the company will report earnings of ($3.23) per share, with EPS estimates ranging from ($4.35) to ($1.87). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.90. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The business had revenue of $153.30 million during the quarter, compared to analysts’ expectations of $138.63 million. During the same period last year, the business earned $0.29 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis.

A number of brokerages have weighed in on ACOR. ValuEngine cut shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. BidaskClub cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 25th. Zacks Investment Research raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Tuesday, July 3rd. Oppenheimer set a $18.00 price objective on shares of Acorda Therapeutics and gave the company a “hold” rating in a research note on Sunday. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Acorda Therapeutics in a research note on Wednesday, July 25th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $24.31.

Shares of ACOR traded up $0.65 during trading on Friday, reaching $19.20. 19,515 shares of the company traded hands, compared to its average volume of 1,075,778. Acorda Therapeutics has a twelve month low of $15.60 and a twelve month high of $36.35. The stock has a market cap of $890.32 million, a PE ratio of 18.46 and a beta of 1.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.09 and a quick ratio of 3.92.

In related news, insider Lauren M. Sabella sold 5,859 shares of Acorda Therapeutics stock in a transaction that occurred on Thursday, June 28th. The shares were sold at an average price of $27.84, for a total value of $163,114.56. Following the completion of the transaction, the insider now owns 5,306 shares in the company, valued at $147,719.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Scopia Capital Management Lp sold 35,889 shares of Acorda Therapeutics stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $30.06, for a total transaction of $1,078,823.34. The disclosure for this sale can be found here. In the last three months, insiders sold 568,420 shares of company stock valued at $16,829,660. Insiders own 7.80% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Xact Kapitalforvaltning AB lifted its position in shares of Acorda Therapeutics by 20.7% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 10,502 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 1,800 shares during the last quarter. NumerixS Investment Technologies Inc lifted its position in shares of Acorda Therapeutics by 123.5% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 2,100 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Acorda Therapeutics by 2.1% during the 1st quarter. Rhumbline Advisers now owns 110,279 shares of the biopharmaceutical company’s stock worth $2,608,000 after buying an additional 2,268 shares during the last quarter. Aperio Group LLC lifted its position in shares of Acorda Therapeutics by 18.1% during the 1st quarter. Aperio Group LLC now owns 15,709 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 2,403 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Acorda Therapeutics by 2.9% during the 1st quarter. Legal & General Group Plc now owns 96,867 shares of the biopharmaceutical company’s stock worth $2,293,000 after buying an additional 2,727 shares during the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.